India, March 12 -- Broking Jefferies is still optimistic about Divi's Laboratories and has stated that the company is set to benefit from the growing importance of the global GLP-1 drug supply chain. This is because Divi's is expanding its peptide production capabilities and has strong partnerships with global pharmaceutical companies to cater to the growing demand for GLP-1 drugs used to treat diabetes and obesity.

With a market cap of Rs 1.67 lakh crore, the shares of Divis Laboratories Ltd are trading at Rs 6,290. The shares are trading at a PE of 66, whereas their industry's PE is at 27.9, and they have given a return of more than 78% over the last 5 years.

GLP-1 Opportunity Could Drive Divi's Next Growth Phase Broking firm Jefferie...